
AI in Research and Administration
TWINCORE establishes task force

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
The LISA Summer School 2026 takes place from 23 August to 11 September 2026. Registration is open until 31 March.

TWINCORE establishes task force

TWINCORE scientist among 95 new Fellows of prestigious academy

OPERA research project launched to further develop antiviral active substances
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Schröter P, Steppich K, Fernández Carrera L, Song Z, Klein S, Souleiman R, Urbanek-Quaing M, Lietzau A, Schnieders A, Freyer E, Bremer B, León-Lara X, Almeida V, Gutierrez Jauregui R, Von Kaisenberg C, Bruhn M, Meineke C, Kalinke U, Wedemeyer H, Prinz I, Ravens S, Carpentier A, Bartsch Y, Kraft A, Cornberg M
Behrendt P, Neumann-Haefelin C
Prallet S, Maier N, Li A, Afting C, Huang H, Hu J, Toprak E, Keya D, Colasanti O, León-Janampa N, Marlet J, Beisel C, Mogler C, Puchas P, Behrendt P, Boettler T, Steinmann E, Saha S, Laketa V, Lohmann V, Wittbrodt J, Hermann C, Dill M, Dao Thi V
Immunomodulatory drugs can have systemic side effects. This project is testing nanocarriers that deliver drugs specifically into myeloid immune cells in order to reduce side effects and increase the local effect.
The project is researching how the effect of monoclonal antibodies can be improved. These antibodies are already being used successfully against viruses. The aim is to optimize the so-called Fc effector functions in order to fight infections even more effectively.
We develop high-throughput screening assays to identify antiviral molecules against RSV and SARS-CoV-2. We use compound libraries, investigate new mechanisms of action and strive for innovative therapies.
Thanks to high-throughput sequencing, genome sequences of hundreds of bacterial strains can be analyzed efficiently, revealing differences of up to 60 % in gene content, as in E. coli. With the help of machine learning, we want to better predict the functions of accessory genes and decipher their contribution to survival in specialized niches.
"Challenge Orphan medicines – learnings from the past"
"Interaction with regulators, e.g. in preparation of a first clinical study"
"Why is knowledge in regulatory science important for translational medicine and basic science?"

